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Abstract 
Furin, a KEX2 protease homolog with high RNA expression in the liver is an excellent candidate as a hepatic proprotein convertase. Here we 
show that purified recombinant furin has the same proalbumin specificity and serpin inhibitory properties as the in situ hepatic convertase. There 
was rapid cleavage at the -RRD- site of normal human proalbumin but there no significant cleavage of natural unprocessed variants with cleavage 
site sequences of -RRV-, -HRD-, -RQD-, or -CRD-. Cleavage of the latter was not increased by S-aminoethylation. Furin was specifically inhibited 
by a,-antitrypsin Pittsburgh (358 Met+Arg), (D = 3 ,LM) but not by 50 PM normal antitrypsin M or by antithrombin, however, antithrombin/ 
heparin was a good inhibitor (KY* = 9pM). The p fI optimum for proalbumin cleavage was between pH 5.5 and 6.0, indicating that furin is potentially 
fully active within secretory vesicles, the site of proalbumin cleavage. 
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1. Introduction 
Since the discovery of the structure of proinsulin 25 
years ago [l], there has been an intensive search for the 
endoprotease involved in the cleavage of prohormones 
and proproteins at di- and multibasic sequences prior to 
their secretion. The identification of the yeast KEX2 
gene product as being responsible for the cleavage of 
pro-a-factor and prokiller toxin at Lys Arg sequences [2] 
led to the identification of a series of mammalian cDNA 
homologs (furin, PC2, PC1/3, PC4, PACE4 and PC6) of 
this subtilisin-like protease [3-lo]. Co-expression of 
these putative convertases with proprotein substrates es- 
tablished that they were indeed capable of cleaving target 
substrates [l l-131, and more recently, recombinant 
forms have been expressed in mammalian cells and the 
encoded proteases isolated from cell supernatants [lC 
171. This advance has facilitated the characterization of 
their pH optima, substrate specificities and inhibitory 
profiles with class-directed inhibitors. Not too surpris- 
ingly, in general terms, these enzymes have been found 
to be KEX2-like but with differences in the basic se- 
quences that they recognize. 
Just as the kex2 mutants of S. cerevisiae led to the 
identification of the yeast convertase, mutations in hu- 
mans that prevented the processing of proalbumin at its 
diarginyl site, permitted the prediction of the specificity 
*Corresponding author. Fax: (64) (3) 364 0750. 
and serpin inhibitory profile of the in situ hepatic conver- 
tase. These predictions were that: (i) the protease should 
cleave the propeptide Arg-6-Gly-Val-Phe-Arg-Arg-1 
from the N-terminal of proalbumin, but not cleave the 
variants proalbumin Lille (-2 Arg+His) and proalbu- 
min Christchurch (-1 Arg+Gln), which make up 50% 
of the serum albumin in heterozygous carriers; (ii) it 
should be a serine protease inhibitable by the reactive 
center variant a,-antitrypsin Pittsburgh (358 Met+Arg) 
but not by normal antitrypsin M or the other major 
liver-derived Arg serpin, antithrombin [18-201. A Ca2+- 
dependent KEXZlike protease with these precise prop- 
erties was subsequently identified in hepatic Golgi secret- 
ing vesicles [21]. The existence of a similar, if not identi- 
cal, KEX-2-like hepatic protease has been confirmed by 
others [22,23]. 
The more recent detection of the circulating proalbu- 
min variants, Blenheim (1 Asp+Val) and Kaikoura (-2 
Arg+Cys) further refine the predicted specificity of the 
in situ convertase. Heterozygous carriers of the Blenheim 
mutation have 10% proalbumin, and 40% mature albu- 
min Blenheim in circulation [24], but it is not known 
whether this reflects a total failure of in situ processing 
with subsequent partial circulating cleavage by an un- 
known protease, or simply reflects partial cleavage by 
the hepatic convertase. It has, however, been shown that 
hepatic secretory vesicle extracts fail to cleave this sub- 
strate [24] and that transfected COS-1 cells secrete the 
unprocessed proalbumin [25]. Proalbumin Kaikoura (-2 
Arg-+Cys) comprises only 3-5% of the circulatory albu- 
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Fig. 1. Cleavage of human proalbumin variants by 4704 furin. Each reaction contained 10 fig of proalbumin in 3 ~120 mM MES, 1 mM CaCl, pH 
7.0 containing 1 mg/l ml a globin. To this was added 0.33 ~1 (4.5 m units) of furin and incubation was carried out at 30°C for 0, 3 and 6 h. The 
reactions were stopped by freezing and then analyzed by agarose gel electrophoresis at pH 8.6 with Coomassie blue staining, anode at top. Lanes 
1 and 20: mature serum albumin marker. Lanes 24: proalbumin Lille 0, 3 and 6 h incubation. Lanes 5-7: proalbumin Christchurch 0, 3 and 6 h 
incubation. Lanes 8-10: normal human proalbumin 0, 3 and 6 h incubation. Lanes 1 l-13: proalbumin Kaikoura incubated 0, 3 and 6 h incubation. 
Lanes 1416: proalbumin Blenheim 0,3 and 6 h incubation. Lanes 17719: aminoethylated proalbumin Kaikoura incubated 0,3 and 6 h. The cleavage 
site sequence of each variant is indicated. 
min in heterozygotes, the remainder being Arg-albumin 
(30%) and mature albumin (63-64%) [26]. The Arg-albu- 
min results from the new Cys acting as a site for cleavage 
by the signal peptidase, but of the expected 20% proalbu- 
min that would reach the secretory vesicles, it is not clear 
if there is partial processing to give the observed plasma 
level, or no processing with subsequent slow cleavage 
during the 18 day half-life of albumin. Notwithstanding 
these limitations, it is clear that, at best, proalbumin 
Blenheim and Kaikoura are poor substrates of the in situ 
convertase. 
Although furin mRNA is ubiquitously expressed, its 
high level in the liver makes it a candidate hepatic con- 
vertase. Here we investigate the proalbumin specificity 
and serpin inhibitory profile of a purified truncated (sol- 
uble) form of furin in order to determine if it has the 
predicted properties of the in situ proalbumin conver- 
tase. 
2. Materials and methods 
Human proalbumin and antitrypsin Pittsburgh were 
isolated from the plasma of the affected child as de- 
scribed earlier [ 191. Antithrombin was isolated from nor- 
mal human plasma by heparin affinity and QAE-Se- 
phadex chromatography [27]. Antitrypsin M was also 
purified from normal plasma, and variant proalbumins 
were isolated from the plasma of heterozygous carriers 
[26]. S-Aminoethylation of the Cys residues at positions 
-1 and 34 of proalbumin Kaikoura was carried out as 
previously described [28]. 
The establishment of the CH0 cell line, CHO/d704, 
expressing the 4704 mutant of mouse furin has been 
previously described as has the purification of this C- 
terminally truncated form of the enzyme [ 161. The major 
81/83 kDa doublet form of the protease was used in this 
investigation and it had a specific activity of 178 units/mg 
[ 161. The purified furin was stored at a concentration of 
13.3 U/ml at -100°C in 10 mM MES, 1 mM CaCl, 
containing 5 mg/ml ovalbumin until required. 
Proalbumin converting activity was assayed by elec- 
trophoresis in 1% agarose gels using Tris-barbitol buffer 
pH 8.6 [19]. Where ‘251-proalbumin was used, approxi- 
mately 100,000 cpm was incubated with the protease and 
the reaction was terminated by freezing. Prior to electro- 
phoresis, 0.5 ,ul of heterozygous proalbumin Christ- 
church plasma was added as a carrier/internal protein 
marker. In experiments with cold proalbumin, 10 ,ug of 
substrate was used and in some cases, 0.2 ,uCi 63Ni2+ was 
added after incubation, 63Ni autoradiography was per- 
formed prior to Coomassie blue staining [19]. 
Automated protein sequence analysis was performed 
on an Applied Biosystems 471A sequencer using a Prob- 
lott cartidge. 
3. Results 
Furin specifically cleaves the propeptide Arg-Gly-Val- 
Phe-Arg-Arg from the N-terminus of purified human 
proalbumin to generate the more anodal band of mature 
serum albumin (Fig. 1, lanes 8810). Authenticity of 
cleavage to the mature N-terminal sequence of Asp-Ala- 
His- was confirmed by 63Ni2+ autoradiography (not 
shown) [19] and N-terminal sequence analysis of the 
product after transfer to a PVDF membrane. There was 
greater than 90% conversion of normal proalbumin to 
albumin after 3 h incubation (Fig. 1, lanes 8-10) repre- 
senting a reaction rate of greater than 0.2 nmol cleaved/ 
min/unit of furin under these conditions. There was, 
however, no detectable cleavage of the circulating vari- 
ants proalbumin Lille (-2 Arg+His), Christchurch (-1 
Arg-+Gln) or Blenheim (1 Asp+Val) even after twice 
this incubation period (6 h). But there was very minor 
cleavage of proalbumin Kaikoura (-2 Arg+Cys) and its 
S-aminoethylated erivative after the 6 h incubation 
(Fig. 1). This was confirmed with prolonged incubations 
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Fig. 2. (A and B) Serpin inhibitory profile of furin catalyzed cleavage 
of “‘I-human proalbumin. Increasing amounts of the specified serpin 
(O-10 pg) were freeze-dried and redissolved in 2.76 ~1 50 mM MES, 
1 mM CaCl, pH 6.5,l mg/ml a globin and 0.24~1 of furin. The enzyme 
and inhibitor were incubated for 15 min prior to the addition of 0.5 ~1 
of substrate; ‘251-human proalbumin (10’ cpm). The reaction was then 
incubated at 30°C for 3 h and 0.5 ~1 of plasma added as a carrier/ 
marker prior to electrophoresis and autoradiography. (A) lanes 16: 0, 
0.14,0.35, 0.7, 1.4 and 2.8 mg/ml final concentration of antitrypsin M, 
respectively. Lanes 7-l 1: 0, 0.14, 0.35, 0.7 and 1.4 mg/ml antitrypsin 
Pittsburgh. (B) Lanes l-6: as for (A) but using antithrombin. Lanes 
7-11: as for (A) but using antithrombin with 0.2 U heparin. Positive 
trypsin controls were included; 0.9 pug trypsin in 3 ~125 mM phosphate 
buffer pH 7.0 was pre-incubated with the specified serpin and treated 
as above. Lane A12: no added serpin. Lane A13: 0.7 mg/ml antitrypsin 
M. Lane A14: 0.7 mg/ml antitrypsin Pittsburgh. Lane B12: 0.7 mg/ml 
antithrombin. Lane B13: 0.2 U heparin. 
(not shown) which showed that both of these substrates 
were cleaved at approximately 1% of the rate of normal 
proalbumin. 
The recent finding of circulating proalbumin in associ- 
ation with a second case of the Pittsburg mutation [29] 
testifies to the validity of the earlier proposal that the in 
situ proalbumin convertase should be inhibited by an- 
titrypsin Pittsburgh but not normal antitrypsin M or 
other liver-derived Arg-serpins. In order to test whether 
purified furin could meet these criteria, 1251-proalbumin 
was incubated with furin under conditions that allowed 
95% conversion (Fig. 2A, lanes 1 and 7). Increasing con- 
centrations of normal antitrypsin M from 0.14 mg/ml to 
2.8 mg/ml had no effect on conversion (Fig. 2A, lanes 
2-6). In the case of antitrypsin Pittsburgh, however, 50% 
inhibition was achieved at an inhibitor concentration of 
0.14 mg/ml (Fig. 2A, lanes 8-11). By way of positive 
controls, lane 12 shows the trypsin catalyzed cleavage of 
proalbumin which, as expected, was completely inhibited 
by the presence of 0.7 mg/ml antitrypsin M (lane 13) and 
antitrypsin Pittsburg (lane 14). This concentration of in- 
hibitor represents a 1.4 molar excess over trypsin. The 
furin catalyzed cleavage of proalbumin was resistant to 
inhibition by antithrombin at concentrations from 0.14 
mg/ml to 2.8 mg/ml (Fig. 2B, lanes 2-6). While 0.2 units 
of heparin itself had no effect on furin (lane 7) heparin 
activated antithrombin produced a 50% inhibition of 
proalbumin conversion at a concentration of about 0.5 
mg/ml (lanes 8-11). Again, as a positive control, the 
trypsin catalyzed cleavage of proalbumin was inhibited 
fully by 0.7 mg/ml antithrombin even in the absence of 
heparin (lane 12). 
Serpins usually act as suicide inhibitors with the P, 
residue acting as a bait for the target serine protease [30]. 
The result of this reaction is usually the formation of a 
tetrahedral complex between the active site serine of the 
protease and the carbonyl carbon of the P, residue. This 
reaction can then proceed to an acyl protease complex 
and becomes irreversible. We examined the reversibility 
of formation of the antitrypsin-furin complex by at- 
tempting to regenerate proalbumin cleavage ability in the 
presence of excess thrombin. Antitrypsin Pittsburgh is an 
excellent inhibitor of thrombin. Thrombin itself, how- 
ever, does not cleave proalbumin (Fig. 3, lane 5) nor does 
it impede furin’s ability to do so (lane 4). The ability of 
antitrypsin Pittsburgh to inhibit furin (lane 2) was re- 
versed if excess thrombin was added to the Pittsburgh- 
furin complex prior to the addition of substrate (lane 3). 
Thrombin is, in effect, able to titrate the antitrypsin Pitts- 
burgh off furin, indicating that there is unlikely to be a 
covalent bond between them. 
Two separate reports place the pH optimum of furin- 
catalyzed hydrolysis of Boc-Arg-Val-Arg-Arg-MCA at 
just over 7, with 50% activity extending between pH 6 
1 a 3 4 
Fig. 3 Autoradiograph showing the reversibility of antitrypsin Pitts- 
burgh inhibition of furin catalyzed cleavage of proalbumin. Lane 1: 0.2 
~1 furin + proalbumin. Lane 2: 0.2 ~1 furin + 1.5 pg antitrypsin Pitts- 
burgh + proalbumin. Lane 3: 0.2 ~1 furin + 1.5 ,ug antitrypsin Pitts- 
burgh + 2.5 pg thrombin and proalbumin. Lane 4: 0.2 ~1 furin + 2.5 
pug thrombin + proalbumin. Lane 5: 2.5 fig thrombin + proalbumin. 
Reactions were carried out in a total volume of 3.75 ~1 50 mM MES 
pH 6.5,l mM CaCl, 1 mg/ml a globin. Antitrypsin Pittsburgh and furin 
were preincubated for 20 min, thrombin was then added and the reac- 
tion incubated for a further 20 min to permit possible dissociation of 
complexes. Proalbumin was then added to all tubes which were incu- 
bated for 2.5 h at 30°C prior to electrophoresis and autoradiography. 
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Fig. 4 pH Dependence of furin cleavage of “‘I-human proalbumin. All reactions contained 3 ,~l of the specified buffer with contained 1 mg/l a globin. 
To this was added 0.3 p1(6x104 cpm) ‘Z51-proalbumin a d 0.2 ~1 of furin, incubation was for 2 h at 30°C. Lanes 1-3: 50 mM acetate, 1 mM CaClz 
pH 4.5, 5.0 and 5.5, respectively. Lanes 48: 50 mM MES, 1 mM CaCl, pH 5.0, 5.5, 6.0, 6.5 and 7.0, respectively. Lanes 9912: 50 mM Hepes/Tris, 
1 mM CaCl, pH 6.5, 7.0, 7.5 and 8.0, respectively. 
and 8.5 [16,17]. When assayed by proalbumin conver- 
sion, however, the pH optimum was between 5.5 and 6.0 
in 50 mM MES buffer; 90% of this activity was retained 
at pH 5.0 but less than 10% activity was retained at pH 
7.0 (Fig. 4). Confirmatory results were obtained in 50 
mM acetate which showed 90% activity at pH 5.0 and 
zero activity at pH 4.5. In 50 mM Hepes/Tris, activity 
was barely detectable at pH 7.0 and none was detected 
at pH 7.5 or 8.0. 
4. Discussion 
The availability of naturally occurring unprocessed 
variants of human proalbumin allowed a direct compar- 
ison of furin to the in situ convertase. Furin has the same 
proalbumin specificity as the in situ enzyme giving rapid 
cleavage of normal proalbumin (cleavage site sequence 
-Arg-Arg-Asp-), but no significant cleavage of the phys- 
iologically unprocessed variants Lille, Christchurch or 
Blenheim with respective processing site sequences of 
-His-Arg-Asp- , -Arg-Gln-Asp- , or -Arg-Arg-Val- (Fig. 
1). The very minor cleavage at the Cys Arg Asp site of 
proalbumin Kaikoura is unlikely to be of physiological 
significance, but it is of interest that aminoethylation of 
this Cys to a Lys analogue did not significantly alter the 
slow cleavage rate, supporting the proposal [31] that 
hepatic processing at adjacent dibasic sites requires an 
Arg-Arg rather than a Lys-Arg sequence. In contrast, the 
yeast KEX2 protease cleaves aminoethylated proalbu- 
min Kaikoura at the same rate as normal proablumin 
v31. 
Since neither furin, the hepatic Golgi vesicle convert- 
ing activity [24], nor co-transfection of COS cells [25] 
produce any significant cleavage of proalbumin Blen- 
heim it raises the question why does plasma contain 10% 
proalbumin and 40% mature albumin Blenheim? The 
most reasonable explanation in that, like proalbumin 
Lille or Christchurch which form 50% of the circulating 
albumin in heterozygotes, it is initially exported unproc- 
essed, but undergoes specific proteolysis in circulation. 
Once activated, the coagulation zymogens cleave their 
targets at specific arginyl sites, which ae frequently fol- 
lowed by a hydrophobic residue (e.g. factor X,, XII, and 
thrombin activate factor VII by cleavage at a Gly Arg 
Ile site and factor XII, cleaves factor XI at a Pro Arg Ile 
site). We have shown (unpublished) that prolonged incu- 
bation with thrombin leads to cleavage of proalbumin 
Blenheim (-RRV-) but not proalbumin Lille (-HRD-) 
supporting the notion that, physiologically, proalbumin 
Blenheim is specifically cleaved in circulation by acti- 
vated coagulation factors. 
The only instance where normal proalbumin, with an 
intact processing site sequence, has been found in circu- 
lation, was in association with a mutation at the P, inhib- 
itory site of ol,-antitrypsin Pittsburgh. This 358 
Met+Arg mutation abolished the inhibitor’s ability to 
inhibit its physiological substrate, leukocytic elastase, 
and instead, targeted it against serine proteases that 
cleaved at Arg residue [32]. This provided an explanation 
for the circulatory proalbumin: the conversion was being 
blocked by the new inhibitor [19] which is co-secreted 
with proalbumin from hepatic secretory vesicles [33]. 
This explanation was supported by co-expression exper- 
iments [34] and the recent finding of circulatory proalbu- 
min in association with a second de novo Pittsburgh 
mutation [29] validates the proposal that antitrypsin 
Pittsburgh is an in situ inhibition of liver conversion and 
the corollary to this, that neither normal antitrypsin or 
its P, Arg homolog antithrombin (minus heparin) are 
such inhibitors. The demonstration that antitrypsin 
Pittsburgh specifically inhibited the yeast-KEX2 pro- 
tease helped validate KEX2 as a model mammalian con- 
vertase and indeed, was the first substantial indication 
that the KEX2 enzyme was a serine protease [35]. 
The recent finding that recombinant antitrypsin Pitts- 
burgh, when present at 0.5 mg!ml, did not inhibit the 
furin catalyzed cleavage of anthrax toxin protective anti- 
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gen [ 171 cast doubt on both the Pittsburgh prediction and 
furin’s potential role as an in vivo convertase. This find- 
ing, however, is at variance with the demonstration that 
furin’s cleavage of proC3 reached 50% inhibition at an- 
titrypsin Pittsburgh concentrations of 0.1 mg/l but was 
unaffected by the highest concentration of normal an- 
titrypsin M used (0.4 mg/l) [36]. 
The results presented here clearly show that furin’s 
serpin inhibitory profile precisely matches that of the in 
situ hepatic convertase, with no inhibition by antitrypsin 
M or antithrombin even at concentrations of 2.8 mg/ml, 
but with 50% inhibition by antitrypsin Pittsburgh at 0.14 
mg/ml. These results contrast markedly with the effects 
of these inhibitors on trypsin, which is inhibited, not only 
by both forms of antitrypsin, but also by antithrombin 
in the absence of heparin. To be an effective inhibitor of 
coagulation, antithrombin requires activation by heparin 
which is located on endothelial surfaces. The need to 
produce antithrombin in a latent form, however, might 
be unrelated to its role as an anticoagulant; it may be to 
prevent it acting as an inhibitor of proprotein conversion 
during antithrombin’s ecretion for the hepatocyte. Cer- 
tainly, activated antithrombin is a good inhibitor of furin 
(ZQ/,, 0.5 mg/ml). 
Previous reports using fluorogenic peptide substrates 
placed furin’s pH optimum that just over pH 7 [16,17], 
casting doubt on its potential role in the acidic environ- 
ment of the secretory vesicle. The findings here, however, 
show that with a more physiologically relevant substrate, 
its activity is an order of magnitude greater between pH 
5.5 and 6.0 than it is at pH 7.0. This parallels the findings 
with a recombinant mouse prorenin substrate (M2Rm4) 
where the pH optimum for cleavage was reported to be 
6.0 [37]. 
This lower pH optimum has important implications; 
it indicates that the protease could be involved in post 
Golgi cleavage. This, together with the proalbumin spec- 
ificity and serpin inhibitory properties as the in situ con- 
vertase, give furin the hallmarks of an authentic hepatic 
convertase. 
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